Enanta Pharmaceuticals (ENTA) Cash from Operations (QoQ) (2012 - 2026)
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Cash from Operations (QoQ) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Enanta Pharmaceuticals | 404.93 Mn | 215.43 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.35% |
| Mar 31, 2026 | 38.83% |
| Dec 31, 2025 | -80.29% |
| Sep 30, 2025 | -137.07% |
| Jun 30, 2025 | 229.79% |
| Mar 31, 2025 | 19.72% |
| Dec 31, 2024 | -61.55% |
| Sep 30, 2024 | 29.61% |
| Jun 30, 2024 | 48.34% |
| Mar 31, 2024 | -14.46% |
| Dec 31, 2023 | -15.67% |
| Sep 30, 2023 | 32.76% |
| Jun 30, 2023 | -133.10% |
| Mar 31, 2023 | 61.33% |
| Dec 31, 2022 | -129.44% |
| Sep 30, 2022 | 47.52% |
| Jun 30, 2022 | -12.24% |
| Mar 31, 2022 | -98.74% |
| Dec 31, 2021 | 36.87% |
| Sep 30, 2021 | 28.76% |